tiprankstipranks
Trending News
More News >
Bone Therapeutics S.A. (GB:0R55)
LSE:0R55
UK Market

Bone Therapeutics (0R55) Ratios

Compare
2 Followers

Bone Therapeutics Ratios

GB:0R55's free cash flow for Q4 2024 was €0.00. For the 2024 fiscal year, GB:0R55's free cash flow was decreased by € and operating cash flow was €0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
0.12- 0.12 0.45 2.14
Quick Ratio
0.12- 0.12 0.45 1.81
Cash Ratio
<0.01- <0.01 0.18 1.43
Solvency Ratio
-0.88- -0.88 -0.08 -0.49
Operating Cash Flow Ratio
-0.22- -0.22 -0.18 -1.92
Short-Term Operating Cash Flow Coverage
-0.29- -0.29 -0.24 -10.21
Net Current Asset Value
€ -30.42M-€ -30.42M€ -21.57M€ -12.25M
Leverage Ratios
Debt-to-Assets Ratio
2.95- 2.95 0.71 1.05
Debt-to-Equity Ratio
-1.23- -1.23 5.91 -3.07
Debt-to-Capital Ratio
5.37- 5.37 0.86 1.48
Long-Term Debt-to-Capital Ratio
-2.12- -2.12 0.82 -0.51
Financial Leverage Ratio
-0.42- -0.42 8.32 -2.92
Debt Service Coverage Ratio
-0.38- -0.38 -0.15 -0.45
Interest Coverage Ratio
-1.18- -1.18 -8.34 -14.23
Debt to Market Cap
18.24- 3.27 2.06 0.25
Interest Debt Per Share
0.25- 0.25 0.18 1.02
Net Debt to EBITDA
-4.13- -4.13 -8.41 -13.06
Profitability Margins
Gross Profit Margin
100.00%-100.00%77.44%98.70%
EBIT Margin
-1296.32%--1296.32%-871.43%-92.20%
EBITDA Margin
-1251.57%--1251.57%-848.87%-86.40%
Operating Profit Margin
-1296.50%--1296.50%-871.43%-1202.60%
Pretax Profit Margin
-5345.86%--5345.86%-1146.24%-1283.60%
Net Profit Margin
-5299.82%--5299.82%-767.29%-1292.50%
Continuous Operations Profit Margin
-5344.57%--5344.57%-1146.24%-98.40%
Net Income Per EBT
99.14%-99.14%66.94%100.69%
EBT Per EBIT
412.33%-412.33%131.54%106.74%
Return on Assets (ROA)
-301.06%--301.06%-6.96%-65.37%
Return on Equity (ROE)
296.89%-125.60%-57.88%191.06%
Return on Capital Employed (ROCE)
112.01%-112.01%-12.22%-91.81%
Return on Invested Capital (ROIC)
-119.41%--127.14%-5.68%-84.38%
Return on Tangible Assets
-438.02%--438.02%-19.95%-65.45%
Earnings Yield
-9130.43%--343.14%-17.70%-91.07%
Efficiency Ratios
Receivables Turnover
1.63- 1.63 0.00 0.00
Payables Turnover
0.00- 0.00 0.03 0.14
Inventory Turnover
0.00- 0.00 0.00 <0.01
Fixed Asset Turnover
0.78- 0.78 0.19 1.16
Asset Turnover
0.06- 0.06 <0.01 0.05
Working Capital Turnover Ratio
-0.06- -0.06 0.28 0.12
Cash Conversion Cycle
224.51- 224.51 -12.11K 59.72K
Days of Sales Outstanding
224.51- 224.51 0.00 0.00
Days of Inventory Outstanding
0.00- 0.00 0.00 62.30K
Days of Payables Outstanding
0.00- 0.00 12.11K 2.58K
Operating Cycle
224.51- 224.51 0.00 62.30K
Cash Flow Ratios
Operating Cash Flow Per Share
-0.03- -0.03 -0.02 -0.60
Free Cash Flow Per Share
-0.03- -0.03 -0.02 -0.61
CapEx Per Share
0.03- 0.00 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
1.00- 1.00 1.00 1.02
Dividend Paid and CapEx Coverage Ratio
-0.99- 0.00 -382.00 -61.76
Capital Expenditure Coverage Ratio
-0.99- 0.00 -382.00 -61.76
Operating Cash Flow Coverage Ratio
-0.12- -0.12 -0.09 -0.61
Operating Cash Flow to Sales Ratio
-6.39- -6.39 -7.18 -12.78
Free Cash Flow Yield
-231.09%--41.37%-16.60%-91.53%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-0.01- -0.29 -5.65 -1.10
Price-to-Sales (P/S) Ratio
2.77- 15.45 43.36 14.19
Price-to-Book (P/B) Ratio
-0.01- -0.37 3.27 -2.10
Price-to-Free Cash Flow (P/FCF) Ratio
-0.43- -2.42 -6.02 -1.09
Price-to-Operating Cash Flow Ratio
-0.09- -2.42 -6.04 -1.11
Price-to-Earnings Growth (PEG) Ratio
>-0.01- >-0.01 0.06 0.03
Price-to-Fair Value
-0.01- -0.37 3.27 -2.10
Enterprise Value Multiple
-4.35- -5.36 -13.52 -29.49
Enterprise Value
29.55M- 36.43M 30.52M 25.48M
EV to EBITDA
-4.35- -5.36 -13.52 -29.49
EV to Sales
54.41- 67.09 114.74 25.48
EV to Free Cash Flow
-8.51- -10.50 -15.94 -1.96
EV to Operating Cash Flow
-8.51- -10.50 -15.98 -1.99
Tangible Book Value Per Share
-0.19- -0.19 -0.13 -0.32
Shareholders’ Equity Per Share
-0.17- -0.17 0.03 -0.32
Tax and Other Ratios
Effective Tax Rate
<0.01- <0.01 0.33 >-0.01
Revenue Per Share
<0.01- <0.01 <0.01 0.05
Net Income Per Share
-0.21- -0.21 -0.02 -0.61
Tax Burden
0.99- 0.99 0.67 1.01
Interest Burden
4.12- 4.12 1.32 13.92
Research & Development to Revenue
6.89- 6.89 3.87 11.68
SG&A to Revenue
6.72- 6.72 2.33 1.77
Stock-Based Compensation to Revenue
0.00- 0.00 0.00 -0.10
Income Quality
0.12- 0.12 0.82 1.06
Currency in EUR